Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagloxad Simolenin (OBI-822)/OBI-821 in high-risk early Globo H-positive TNBC
CTR20211603Phase 3Terminated
- Sponsor
- OBI Pharma
- Start
- Jul 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of adagloxad simolenin in triple-negative breast cancer (TNBC), sponsored by OBI Pharma. Started Jul 2021; status: terminated.
02
Drugs
adagloxad simolenin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20211603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211603.